DA
CSTL icon

Denali Advisors’s Castle Biosciences CSTL Stock Holding History

Denali Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,400
Closed -$186K – 248
2024
Q1 		$186K Buy
+8,400
New +$183K 0.05% 235

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Denali Advisors's CSTL Position: Q2 2024 in Review

Denali Advisors sold out of Castle Biosciences (CSTL) in Q2 2024, closing a stake of 8,400 shares — an estimated $186K sold.

Denali Advisors first reported a position in CSTL in Q1 2024 and held it in 1 quarter. The position peaked at $186K in Q1 2024. 159 funds tracked by Wall St. Rank hold CSTL as of Q2 2024.

  • Denali Advisors reported no remaining Castle Biosciences position as of Q2 2024 after selling out during the quarter.
  • Denali Advisors sold 8,400 Castle Biosciences shares in Q2 2024, an estimated $186K.
  • Denali Advisors first reported a position in Castle Biosciences in Q1 2024 and held it in 1 quarter.
  • Denali Advisors's Castle Biosciences position peaked at $186K in Q1 2024.
  • 159 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2024.

Based on Denali Advisors's 13F filing for Q2 2024, filed 9 Aug 2024.